$756.3 M

ITCI Mkt cap, 04-Dec-2018
Intra-Cellular Therapies Net income (Q2, 2018)-72.9 M
Intra-Cellular Therapies EBIT (Q2, 2018)-76.3 M
Intra-Cellular Therapies Cash, 30-Jun-201869.8 M

Intra-Cellular Therapies Revenue Breakdown

Embed Graph

Intra-Cellular Therapies revenue breakdown by business segment: 33.6% from License and collaboration revenue and 66.4% from Grant Revenue

Intra-Cellular Therapies Income Statement

Annual

USDFY, 2013FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

2.7m2.7m577.3k91.4k330.7k245.8k

Revenue growth, %

(79%)(84%)262%

R&D expense

23.0m21.2m87.7m93.8m79.4m

General and administrative expense

6.0m10.3m18.2m24.8m23.7m

Operating expense total

29.0m31.6m105.9m118.6m103.1m

EBIT

(26.3m)(26.3m)(31.0m)(105.8m)(118.3m)(102.8m)

EBIT margin, %

(960%)(960%)(5368%)(115816%)(35760%)(41833%)

Interest expense

613.0k613.0k7.1k36.8k

Interest income

29.6k29.6k303.9k1.0m2.9m4.0m

Pre tax profit

(30.7m)(104.8m)(115.4m)

Income tax expense

(18.0k)(18.0k)1.6k(1.6k)1.1m(1.1m)

Net Income

(26.9m)(26.9m)(30.7m)(104.8m)(116.4m)(97.8m)

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

Revenue

668.0k167.8k219.2k124.4k3.3k57.4k124.4k3.3k228.4k4.4k95.3k114.7k30.8k

R&D expense

4.2m2.8m2.7m4.0m18.6m17.8m28.5m23.4m25.3m23.9m21.5m12.5m18.5m30.7m63.1m

General and administrative expense

1.3m1.9m2.1m2.6m3.8m4.0m3.9m5.1m6.5m6.3m6.3m6.3m5.3m6.4m13.1m

Operating expense total

5.5m4.7m4.8m6.6m22.4m21.7m32.3m28.5m31.8m30.2m27.8m18.7m23.8m37.1m76.3m

EBIT

(4.8m)(4.6m)(4.6m)(6.5m)(22.4m)(21.7m)(32.3m)(28.5m)(31.5m)(30.2m)(27.8m)(18.6m)(23.8m)(37.1m)(76.3m)

EBIT margin, %

(716%)(2726%)(2103%)(5227%)(675739%)(37796%)(26001%)(859664%)(13808%)(691985%)(29127%)(16227%)(77256%)

Interest expense

131.9k5.0k2.0k5.0k12.3k

Interest income

5.6k36.2k80.1k88.1k113.9k179.6k188.9k656.4k709.6k763.9k822.2k857.8k884.8k1.6m3.4m

Pre tax profit

(29.4m)(26.9m)(17.8m)(22.9m)(35.5m)(72.9m)

Income tax expense

(832.6k)1.6k1.6k4.0k1.6k

Net Income

(4.9m)(4.5m)(4.5m)(6.4m)(22.3m)(21.5m)(32.2m)(27.8m)(30.8m)(30.3m)(26.9m)(17.8m)(22.9m)(35.5m)(72.9m)

Intra-Cellular Therapies Balance Sheet

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

35.2m61.3m47.2m48.6m37.8m

Accounts Receivable

336.3k51.6k30.7k94.3k

Inventories

762.2k1.3m8.0m4.0m

Current Assets

38.2m131.0m483.3m388.2m469.2m

PP&E

68.3k54.6k775.5k627.6k1.1m

Total Assets

38.4m131.1m484.1m388.9m471.5m

Accounts Payable

3.4m2.1m1.6m3.8m6.2m

Short-term debt

Current Liabilities

6.8m10.6m6.3m10.5m14.2m

Long-term debt

Total Debt

Total Liabilities

7.9m13.4m17.0m

Additional Paid-in Capital

89.2m208.9m669.9m685.3m862.5m

Retained Earnings

(57.6m)(88.3m)(193.0m)(309.5m)(407.2m)

Total Equity

31.6m120.6m476.2m375.5m454.4m

Financial Leverage

1.2 x1.1 x1 x1 x1 x

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

Cash

44.1m143.6m91.1m68.9m100.8m71.4m332.8m37.2m52.0m200.4m23.6m29.6m52.3m74.4m69.8m

Accounts Receivable

251.3k167.8k219.2k124.4k3.3k9.1k51.6k98.2k1.3k68.2k61.9k6.3k

Current Assets

47.1m146.4m141.2m137.5m236.5m212.6m512.3m462.9m446.8m541.8m371.6m348.8m333.4m443.2m409.7m

PP&E

75.7k65.1k63.9k57.4k559.7k722.1k785.5k731.4k718.7k677.7k605.7k628.9k679.6k1.3m1.3m

Total Assets

47.3m146.6m141.3m137.6m237.1m213.4m513.1m463.7m447.6m542.6m372.3m349.5m334.2m445.6m412.1m

Accounts Payable

4.0m2.1m415.8k503.9k4.6m4.9m705.0k2.0m3.9m5.4m7.2m1.8m4.4m10.0m5.4m

Current Liabilities

7.8m3.9m2.7m3.6m14.6m9.3m10.4m8.9m19.4m140.7m16.3m7.0m11.9m19.7m18.9m

Total Liabilities

14.8m9.8m11.3m10.9m21.6m143.3m19.3m9.9m14.8m22.5m21.7m

Additional Paid-in Capital

89.1m204.8m205.3m207.2m332.9m335.7m666.1m673.7m677.6m681.5m689.7m694.1m696.7m867.2m871.5m

Retained Earnings

(49.5m)(62.1m)(66.6m)(73.1m)(110.5m)(132.1m)(164.2m)(220.9m)(251.7m)(282.0m)(336.4m)(354.2m)(377.0m)(442.7m)(480.1m)

Total Equity

39.6m142.7m138.6m134.0m222.4m203.6m501.9m452.7m426.0m399.3m353.0m339.7m319.4m423.2m390.4m

Financial Leverage

1.2 x1 x1 x1 x1.1 x1 x1 x1 x1.1 x1.4 x1.1 x1 x1 x1.1 x1.1 x

Intra-Cellular Therapies Cash Flow

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(26.9m)(30.7m)(104.8m)(116.4m)(97.8m)

Depreciation and Amortization

23.2k25.5k139.6k196.9k213.9k

Accounts Receivable

(35.9k)284.7k20.9k(63.7k)94.3k

Inventories

Accounts Payable

3.4m(1.3m)(419.9k)2.1m2.4m

Cash From Operating Activities

(22.6m)(22.8m)(102.3m)(91.3m)(80.5m)

Purchases of PP&E

(33.3k)(11.8k)(860.6k)(49.0k)(723.4k)

Cash From Investing Activities

1.5m(66.7m)(361.8m)92.3m(92.7m)

Cash From Financing Activities

40.6m115.7m449.9m477.7k162.4m

Interest Paid

11.3k7.1k7.1k36.8k

Income Taxes Paid

31.4k45.0k1.0m

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

Net Income

(4.9m)(4.5m)(9.1m)(6.4m)(22.3m)(43.8m)(32.2m)(27.8m)(58.7m)(88.9m)(26.9m)(44.7m)(67.6m)(35.5m)(72.9m)

Depreciation and Amortization

6.3k12.7k47.1k48.0k96.7k146.8k50.4k101.8k155.3k82.5k178.3k

Accounts Receivable

168.5k117.1k124.4k3.3k42.5k51.6k30.7k(67.6k)29.4k26.1k32.4k88.0k

Accounts Payable

(1.3m)(3.0m)503.9k4.6m2.9m705.0k326.4k2.3m3.8m3.4m(2.0m)653.0k3.9m(794.7k)

Cash From Operating Activities

(7.0m)(12.2m)(46.7m)(19.7m)(33.1m)(62.8m)(16.4m)(41.3m)(55.7m)(27.0m)(60.6m)

Purchases of PP&E

(3.1k)(8.3k)(714.7k)(3.9k)(39.9k)(49.0k)(28.5k)(103.1k)(207.3k)(295.1k)(316.5k)

Cash From Investing Activities

(3.1k)(47.5m)(65.3m)9.6m37.6m90.6m(8.9m)22.0m59.2m63.3m92.2m

Cash From Financing Activities

115.5m115.6m122.1m163.7k348.0k125.5m224.2k230.8k230.8k337.8k343.9k

Interest Paid

5.0k7.1k

Income Taxes Paid

3.9k27.9k206.6k

Intra-Cellular Therapies Ratios

USDY, 2018

Financial Leverage

1.1 x
Report incorrect company information

Intra-Cellular Therapies Operating Metrics

FY, 2017

Patents and Patent Applications

80
Report incorrect company information

Intra-Cellular Therapies Employee Rating

00 votes
Culture & Values
N/A
Work/Life Balance
N/A
Senior Management
N/A
Salary & Benefits
N/A
Career Opportunities
N/A
Source